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Abstract	  
Finland	   has	   enacted	   a	   Biobank	   Act	   that	   will	   come	   into	   force	   on	   September	   1,	   2013.	  
Finland	   is	   regarded	   for	   many	   reasons	   as	   a	   highly	   successful	   environment	   for	   medical	  
research	   that	   uses	   population	   samples	   and	   data.	   One	   of	   the	   rationales	   behind	   the	   new	  
legislation	   was	   to	   solve	   problems	   due	   to	   the	   overly	   strict	   informed	   consent	   doctrine	  
hindering	   access	   to	   old	   samples	   and	   data	   and	   asking	   for	   multi-­‐purpose	   consents.	   Yet,	  
consent	  remains	  the	  primary	  justification	  to	  use	  biobank	  samples	  and	  data.	  The	  Biobank	  
Act	   allows	   asking	   for	   consent	   for	   several	   unspecified	   future	   research	   purposes.	   The	  
guiding	  principles	   of	   the	  Biobank	  Act	   are	   promotion	  of	   trust,	   equal	   access	   to	   data	  and	  
samples,	  protection	  of	  privacy,	  acceleration	  of	  innovation	  activities,	  and	  bringing	  biobank	  
activities	  under	  public	  scrutiny.	  To	  the	  author’s	  knowledge,	  this	  is	  the	  first	  “all	  purpose”	  
Biobank	  Act	  in	  Europe	  that	  applies	  to	  all	  biobanks	  in	  a	  country.	  
Main	  features	  of	  the	  new	  law	  Finland	   has	   enacted	   a	   Biobank	   Act	   (Act	   688/2012)1	   that	   will	   come	   into	   force	   on	  September	   1,	   2013.	   At	   the	   same	   time	   provisions	   of	   the	   Tissue	   Act	   that	   regulates	  secondary	   use	   of	   human	   biological	   samples	   will	   become	   amended.	   One	   of	   the	  rationales	  for	  the	  Biobank	  Act	  was	  to	  solve	  problems	  due	  to	  the	  overly	  strict	  informed	  consent	  doctrine	  (i.e.,	   the	   limited	  scope	  of	  the	  consent)	  and	  enable	  secondary	  uses	  of	  old	  samples	  and	  data.	  	  To	  my	  knowledge,	   this	   is	   the	   first	   “all	  purpose”	  Biobank	  Act	   in	  Europe	  applied	   to	  all	  biobanks,	  whether	   clinical	   or	   research	  based,	   public	   or	   private,	   and	   irrespectively	   of	  the	  identifiable	  or	  anonymous	  nature	  of	  data	  and	  samples.	  Clinical	  trials	  and	  other	  one-­‐time	   research	   protocols	   will	   remain	   as	   stipulated	   by	   the	   Medical	   Research	   Act	  (488/1999).	  The	  novelty	  is	  that	  the	  Biobank	  Act	  allows	  asking	  for	  a	  consent	  for	  several	  unspecified	  future	  research	  purposes	  in	  which	  biobank	  samples	  and	  data	  can	  be	  used.	  	  The	  guiding	  principles	  of	  the	  Biobank	  Act	  are	  a	  promotion	  of	  trust,	  equal	  access	  to	  data	  and	  samples,	  protection	  of	  privacy,	  acceleration	  of	   innovation	  activities,	  and	  bringing	  biobank	   activities	   under	   public	   scrutiny.	   Translational	   research,	   personalised	  medicine,	  the	  benefits	  of	  public–private	  collaboration	  and	  the	  optimal	  use	  of	  resources	  for	   the	   ultimate	   goal	   of	   improved	   delivery	   of	   health	   care	   services	   are	   explicitly	  mentioned	  in	  the	  travaux	  preparatoires	  (Governmental	  proposal	  86/2011).	  	  A	   biobank	   owns	   the	   samples	   and	   data	   in	   its	   possession,	   unless	   otherwise	   agreed	  explicitly	   in	   the	   material	   transfer	   agreement.	   A	   biobank	   is	   obliged	   to	   publish	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
∗	  The	  author,	  LL.M	  Sirpa	  Soini	  is	  a	  senior	  legal	  adviser	  at	  the	  National	  Institute	  for	  Health	  and	  Welfare	  (THL),	  Helsinki,	  Finland;	  legal	  adviser	  for	  the	  Finnish	  national	  biobank	  coordination,	  www.bbmri.fi;	  and	  a	  member	  of	  the	  Governmental	  Expert	  Steering	  Group	  for	  the	  Implementation	  of	  the	  Biobank	  Act,	  appointed	  by	  the	  Ministry	  of	  Health	  and	  Social	  Affairs.	  	  
1	  www.finlex.fi	  Finnish	  official	  page	  for	  government	  acts,	  bills,	  case-­‐law	  etc.	  Some	  acts	  have	  been	  translated	  into	  other	  languages,	  but	  the	  Biobank	  Act	  is	  not	  yet	  one	  of	  them.	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   information	   about	   its	   samples	   and	   their	   use	   for	   biobank	   research,	   and	   the	   results	  thereof.	  The	   idea	   is	   that	  data	  will	   accumulate	   in	   the	  biobank	   for	   the	  benefit	   of	   other	  researchers,	   thus	   avoiding	   repetition	   of	   certain	   analyses,	   and	   bringing	   new	   findings	  onto	  a	  common	  platform.	  	  A	  biobank	  can	  collect,	  store,	  analyse	  and	  share	  human	  biological	  samples	  and	  related	  geno-­‐	   and	   phenotype	   data,	   obtained	   directly	   from	   the	   research	   subject	   or	   through	  accessing	   clinical	   data	   and	   health-­‐based	   registries,	   or	   by	   various	   analyses.	   	   Use	   of	  samples	   and	   data	   are	   subject	   to	   strict	   coding	   requirements,	   unless	   otherwise	  consented	  to.	  
Finland’s	  strengths	  in	  biobank	  research	  Finland	  is	  regarded	  for	  many	  reasons	  as	  a	  highly	  successful	  environment	   for	  medical	  research	   that	   uses	   population	   samples	   and	   data.	   First,	   the	   Finns	   have	   a	   relatively	  isolated	   gene	   pool	   which	   is	   an	   advantage	   for	   genetic	   and	   molecular	   studies.2	   The	  unique	   personal	   identity	   numbers,	   introduced	   in	   1964,	   and	   early	   computerised	  registers	   combined	   with	   patient	   records	   and	   biological	   samples	   provide	   a	   rich	   and	  versatile	   source	   for	   public	   health	   research	   and	   longitudinal	   population	   studies.	  Further,	  church	  records	  contain	  information	  about	  births,	  marriages	  and	  deaths	  from	  as	   early	   as	   the	   17th	   century,	   so	   population	   trends	   can	   be	   tracked.3	   Like	   our	  Scandinavian	   neighbours,	   we	   are	   still	   ranked	   high	   regarding	   trust	   in	   biomedical	  science	   and	   in	   the	   state.4	   All	   these	   advantages	   contribute	   to	   successful,	   high	   quality	  research.	  Indeed,	  many	  ongoing	  epidemiological	  studies	  date	  back	  several	  decades,	  and	  their	  value	  as	  a	  research	  resource	  continues	  to	  accumulate.5	  The	  key	  question	  is	  how	  to	  optimally	  use	  these	  resources,	  while	  at	  the	  same	  time	  maintaining	  people’s	  trust.	  	  
Establishment	  of	  a	  biobank	  is	  subject	  to	  ethical	  review	  As	   of	   September	   1,	   2013	   a	   legal	   entity	   can	   establish	   a	   biobank	   in	   Finland.	   The	   legal	  entity	   can	   be	   a	   public	   or	   private	   operator:	   a	   hospital,	   a	   research	   institute,	   a	  pharmaceutical,	  biotechnological	  or	  other	  company,	  a	  foundation,	  inter	  alia,	  as	  long	  as	  its	  economic	  and	  functional	  operations	  as	  well	  as	  legal	  and	  scientific	  preconditions	  are	  adequate.	  A	  single	  researcher	  cannot	  be	  a	  founder,	  but	  he	  or	  she	  can	  transfer	  valuable	  collections	  beneficial	   to	   future	  research	  purposes	   into	  a	  biobank,	  and	  also	  access	   the	  biobanks	  for	  own	  research	  purposes.	  	  An	  application	   for	   an	  ethical	   review	   to	  establish	  a	  biobank	   shall	   be	   submitted	   to	   the	  National	  Medical	   Research	   Ethics	   Committee	   (TUKIJA).	   The	   application	   shall	   contain	  substantial	  amounts	  of	  information	  regarding	  the	  owner,	  funder,	  repository,	  registries,	  field	   of	   activities,	   access	   criteria	   and	   principles,	   consent	   procedures,	   applied	   model	  documents,	  and	  operating	  plans	  with	  a	  description	  of	  the	  organisation,	  responsibilities,	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  2	  See	  L.	  Peltonen,	  A.	  Jalanko,	  T.	  Varilo,	  “Molecular	  genetics	  of	  the	  Finnish	  disease	  heritage”.	  Human	  Molecular	  Genetics,	  1999;	  8	  (10):	  1913-­‐1923.	  3	  See	  M.	  Gissler	  and	  J.	  Haukka,	  “Finnish	  health	  and	  social	  welfare	  registers	  in	  epidemiological	  research”.	  Norsk	  Epidemiologi	  2004;	  14	  (1):	  113-­‐120.	  4	  G.	  Gaskell	  et	  al.,	  “Europeans	  and	  biotechnology	  in	  2010.	  Winds	  of	  change?”	  European	  Commission,	  2010	  (EUR	  24537).	  	  5	  See	  www.nationalbiobanks.fi	  	  These	  pages	  contain	  information	  on	  Finnish	  epidemiological	  and	  clinical	  study	  collections	  and	  their	  availability	  for	  research.	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   and	  breadth	  and	  level	  of	  activities.	  TUKIJA	  has	  sixty	  days	  in	  which	  to	  give	  its	  statement,	  conditional	  on	  no	  further	  information	  being	  needed.	  	  
Commencement	  of	  biobank	  operations	  requires	  registration	  	  Biobanks	   will	   be	   supervised	   by	   the	   National	   Supervisory	   Authority	   for	   Health	   and	  Welfare	   (Valvira).	   Before	   starting	   its	   operations,	   a	   biobank	   must	   file	   a	   register	  application	   to	   Valvira	   to	   be	   registered	   in	   the	   National	   Biobank	   Register.	   The	  application	   shall	   include	   documents	   showing	   the	   legal	   status;	   statement	   of	   TUKIJA;	  nomination	   of	   ”the	   person	   in	   charge	   of	   the	   biobank”	   and	   his	   or	   her	   training	   and	  experience;	   accounts	   for	   risk	   management	   and	   quality	   control;	   organisation	   chart,	  personnel,	   capacities	   and	   responsibilities;	   person	   register	   notifications;	   and	   list	   of	  standard	  operating	  procedures.	  	  Valvira	  guides	   the	  biobank	  activities	  and	  has	  competence	  to	   intervene	   in	   the	  event	   it	  finds	   deficits	   in	   a	   biobank’s	   activities.	   It	   can	  make	   inspections	   and	   give	   orders	   (e.g.,	  obligate	  the	  biobank	  to	  give	  access	  to	  its	  samples	  and	  data)	  and	  injunctions.	  	  
Consent	  is	  the	  primary	  justification	  to	  use	  biobank	  samples	  and	  data	  The	   use	   of	   samples	   and	   data	   for	   biobank	   research	   shall	   be	   primarily	   based	   on	   a	  person’s	   informed	   consent.	   The	   biobank-­‐specific	   consent	   can	   be	   seen	   as	   consent	   for	  inclusion	  of	  samples	  and	  data	  in	  several	  research	  projects	  in	  a	  specified	  biobank.	  Yet,	  there	   are	   still	   some	   who	   consider	   this	   kind	   of	   consent	   to	   be	   too	   broad	   and	   thus	  illegitimate.	  However,	  under	  the	  Biobank	  Act	  the	  person	  shall	  be	  adequately	  informed	  about	  the	  owner	  of	  the	  biobank	  and	  about	  the	  biobank	  which	  stores	  the	  samples	  and	  data,	  as	  these	  may	  be	  different	  bodies.	  The	  registered	  field	  of	  activities	  of	  the	  biobank	  serves	   as	   a	   limitation	   for	   the	   use	   of	   its	   samples	   and	   data.	   Further,	   the	   person	   to	   be	  recruited	  shall	  be	  informed	  of	  the	  general	  nature	  of	  biobanking	  and	  potential	  risks,	  the	  purposes	  of	   collection	  and	   storage,	   the	  voluntariness,	   the	   right	   to	   cancel	   or	   limit	   the	  consent	  at	  any	  time.	  The	  person	  may	  also	  give	  consent	  that	  his	  personal	  data	  may	  be	  disclosed,	  or	  be	  linked	  to	  register	  data.	  	  One	  of	  the	  concerns	  is	  how	  to	  keep	  the	  consent	  valid	  and	  fresh	  in	  the	  course	  of	  time,	  and	  how	  to	  better	  empower	  individuals	  to	  govern	  the	  use	  of	  their	  samples	  and	  data.	  One	  proposed	  solution	  is	  to	  integrate	  the	  management	  of	  one’s	  consent	  into	  the	  National	  Archive	  of	  Health	  Information	  (KanTa),	  which	  is	  currently	  being	  developed	  to	  serve	  health	  care,	  pharmacies	  and	  citizens.	  The	  services,	  once	  fully	  operational,	  will	  include	  electronic	  prescription,	  a	  Pharmaceutical	  Database,	  a	  My	  Health	  Information,	  and	  a	  Patient	  Records	  Archive.	  Ideally,	  a	  person	  could	  then	  manage	  and	  access	  all	  his	  or	  her	  health	  data	  through	  KanTa,	  with	  biobank	  consents	  included.	  This	  might	  be	  a	  step	  towards	  “the	  dynamic	  consent”,	  as	  suggested	  by	  the	  European	  Commission	  Expert	  Group	  in	  2012.6	  Clinical	  and	  research	  samples	  that	  have	  been	  collected	  before	  the	  Biobank	  Act	  comes	  into	   force	   (i.e.,	   September	   1,	   2013),	   can	   be	   transferred	   to	   a	   biobank	   as	   a	   result	   of	   a	  specific	  notification	  procedure	  and	  subsequent	  opt-­‐out	  principle.	  The	  precondition	   is	  that	   a	   regional	   ethics	   committee	   approves	   the	   planned	   transfer.	   In	   addition,	   the	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  6	  European	  Commission,	  “Biobanks	  for	  Europe.	  A	  challenge	  for	  governance”.	  Report	  of	  the	  Expert	  group	  on	  Dealing	  with	  Ethical	  and	  Regulatory	  Challenges	  of	  International	  Biobank	  Research.	  European	  Commission,	  2012	  (EUR	  25302).	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   persons	   involved	   shall	   be	   contacted	   with	   the	   information	   about	   the	   transfer	   into	   a	  biobank,	  with	  the	  idea	  that	   if	  he	  or	  she	  does	  not	  object,	   the	  samples	  and	  related	  data	  will	  be	  transferred	  to	  a	  biobank.	  Should	  the	  samples	  be	  old,	  numerous	  or	  the	  persons	  hard	   to	   reach	   with	   reasonable	   efforts,	   the	   notification	   procedure	   can	   instead	   occur	  through	   public	   media.	   A	   consent	   is	   not	   required	   for	   the	   transfer,	   even	   though	  preferred;	  therefore	  I	  call	  this	  procedure	  an	  opt-­‐out	  mechanism.	  	  The	   Tissue	   Act	   still	   holds	   for	   some	   exemptions	   regarding	   the	   use	   of	   cadaveric,	  diagnostic	   or	   therapeutic	   samples	   and	   tissues	   for	   secondary	   medical	   research	  purposes	   and	   transfer	   into	   biobanks	   under	   certain	   criteria.	  Nevertheless,	   it	   is	  worth	  noting	  that	  research	  samples	  and	  data	  cannot	  be	  used	  for	  secondary	  purposes	  after	  the	  Biobank	  Act	   is	  effective	  without	  a	  new	  consent.	  Thus,	   it	   is	   important	   to	  assess	   future	  needs	  when	  making	  research	  protocols	  to	  incorporate	  potential	  needs	  into	  the	  consent	  procedure.	  Naturally,	   the	  candidate	  biobank	   for	  storage	  shall	  exist	   is	  such	  cases,	  as	  a	  consent	  is	  always	  related	  to	  some	  existing	  biobank	  and	  its	  field	  of	  activities.	  	  
The	  premise	  of	  equal	  access	  to	  biobank	  material	  Biobank	   samples	   and	   data	   can	   be	   used	   for	   biobank	   research	   if	   the	   intended	   use	  complies	  with	  the	  notified	  field	  of	  research	  activities	  for	  a	  given	  biobank	  and	  with	  the	  consent	   or	   other	   basis,	   for	   instance,	   resulting	   from	   the	   transfer	   of	   old	   samples.	   In	  addition,	   research	   and	   handling	   of	   samples	   and	   data	   shall	   follow	   relevant	   laws	   and	  rules,	   and	   the	   recipient	   shall	   have	   an	   appropriate	   professional	   and	   scientific	  competence.	  A	  proper	  link	  to	  recipient’s	  tasks	  is	  also	  required.	  	  A	   party	   wishing	   to	   initiate	   biobank	   research	   has	   a	   right	   to	   access	   the	   biobank’s	  metaregister	  to	  find	  out	  whether	  relevant	  research	  material	  is	  available.	  Once	  a	  party	  desires	  to	  access	  the	  samples	  and	  data,	  it	  shall	  make	  a	  requisition	  along	  with	  a	  research	  plan	  or	  other	  necessary	  specification	  on	  the	  intended	  use.	  Depending	  on	  the	  research	  plan,	  a	  research	  ethics	  review	  may	  also	  be	  needed.	  	  The	   Biobank	   Act’s	   starting	   point	   is	   that	   biobanks	   are	   shared	   research	   resources.	  Therefore,	  the	  provisions	  state	  that	  a	  biobank	  can	  restrict	  delivery	  of	  its	  samples	  and	  data	  only	  if	  justified	  after	  considering	  the	  following	  points:	  -­‐ the	  intended	  use	  is	  against	  the	  biobank’s	  field	  of	  activities	  and	  other	  restrictions,	  -­‐ safeguarding	  ongoing	  primary	  research,	  -­‐ safeguarding	  IPR,	  -­‐ preservation	  of	  rare	  or	  limited	  precious	  collections	  for	  very	  significant	  purposes,	  -­‐ safeguarding	  privacy	  (small	  collection,	  where	  data	  exposure	  is	  likely),	  -­‐ reasons	  related	  to	  research	  ethics.	  	  Same	   access	   criteria	   apply	   to	   both	   the	   biobank’s	   own	   and	   to	   external	   research.	   A	  biobank	  must	  develop	  a	  transparent	  process	  describing	  its	  access	  policy.	  These	  will	  be	  explicitly	  tested	  in	  the	  administrative	  courts,	  if	  necessary.	  
A	  register	  subject’s	  right	  to	  receive	  information	  A	  register	  subject,	  as	  he	  or	  she	  is	  called	  in	  the	  Act,	  can	  ask	  whether	  his	  or	  her	  samples	  are	   being	   stored	   in	   a	   biobank,	   the	   grounds	   for	   storage,	   from	  where	   related	  data	   has	  been	   collected	   and	   to	  where	   disclosed.	   In	   addition,	   a	   register	   subject	   can	   ask	   about	  health-­‐related	  information	  resulting	  from	  the	  analyses,	  in	  which	  case	  he	  or	  she	  shall	  be	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   offered	   a	   possibility	   to	   know	   the	  meaning	   of	   such	   information.	   This	   legal	   obligation	  assigned	   to	  biobanks	   raises	   great	   concerns:	   is	   this	   feasible,	   in	  particular,	   in	   research	  laboratories	   that	   are	   not	   accredited	   for	   clinical	   purposes,	   and	   hence,	   cannot	   usually	  give	  clinically	  valid	  results?	  
Conclusions	  Despite	   some	   ambiguities	   and	   some	   outstanding	   challenges,	   the	   political	   will	   and	  support	  is	  very	  strong	  in	  guiding	  Finnish	  biobanking	  towards	  success.	  It	  is	  also	  obvious	  that	   the	   Biobank	   Act	   was	   long	   awaited	   among	   the	   Finnish	   biobank	   community	   and	  thus,	  all	   the	  relevant	  actors	  are	  committed	  to	  working	  together	  for	  the	  common	  goal.	  For	  instance,	  relevant	  actors	  are	  developing	  harmonised	  data	  standards	  and	  systems,	  consent	  practices	  etc.,	  so	  that	  the	  interoperability	  of	  biobanks	  will	  be	  a	  reality	  from	  the	  beginning.	   The	   focus	   of	   attention	   is	   also	   on	   joining	   the	   European	   wide	   biobank	  research	  infrastructure,	  BBMRI-­‐ERIC,	  a	  legal	  entity	  under	  EU	  legislation.7	  All	   five	   university	   hospitals	   (Helsinki,	   Turku,	  Tampere,	  Kuopio	   and	  Oulu)	  will	   create	  their	  own	  clinical	  biobanks.	  Time	  will	  demonstrate	  if	  and	  how	  they	  specialise	  in	  some	  therapeutic	  areas.	  In	  addition,	  a	  Finnish	  Cancer	  Centre	  is	  likely	  to	  be	  established	  soon.	  Further,	   the	   National	   Institute	   for	   Health	   and	   Welfare	   (THL)	   will	   establish	   a	  population-­‐based	   biobank,	   to	   which	   it	   intends	   to	   transfer	   its	   major	   longitudinal	  cohorts.	  The	  development	  of	  the	  inventory	  is	  ongoing.	  The	  plans	  of	  private	  actors	  are	  so	  far	  unknown.	  	  The	  Ministry	  of	  Health	  and	  Social	  Affairs	  has	  appointed	  an	  expert	  steering	  group	  for	  a	  period	   of	   five	   years	   to	  monitor	   the	   implementation	   and	   functionality	   of	   the	  Biobank	  Act,	  and	  to	  suggest	  amendments	  to	  it,	  when	  considered	  necessary.	  	  The	  momentum	   to	   develop	   a	   strong	   comprehensive	   biobank	   research	   infrastructure	  with	  good	  practices	  remains	  currently	  strong,	  with	   the	  clear	   intention	  of	  overcoming	  hurdles	  and	  identifying	  the	  needs	  of	  all	  the	  stakeholders,	  so	  that	  opportunities	  are	  not	  missed.	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